Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. Data showed an 82% response rate in patients with grades 1 to 3a disease, with 75% of the overal...
Odronextamab is a CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. ELM-1 is an ongoing, open-label, multicenter Phase 1 trial to investigate the safety and tolerability of...
Odronextamab (CD20 and CD3 Bispecific Antibody) - Initiate Phase 3 studies in FL and DLBCL, including earlier lines of therapy (first half 2023) - Submit BLA for relapsed/refractory FL and DLBCL (second half 2023) Linvoseltamab (BCMA and CD3 Bispecific Antibody) - Init...
In April 2020, the Company entered into an agreement with Zai Lab Limited to develop and commercialize REGN1979 (bispecific antibody targeting CD20 and CD3) in mainland China, Hong Kong, Taiwan, and Macau. Under the terms of the agreement, Zai is obligated to make a $30 m...
Odronextamab is an investigational bispecific T-cell engager that works by binding to both the CD20 and CD3 surface proteins, acting as a bridge between cells that express these epitopes. Through this mechanism, odronextamab can facilitate the destruction of CD20-bearing cells ...
REGN1979是Regeneron开发针对CD3和CD20的IgG4型双特异性抗体,包含靶向CD20的重链、靶向CD3的重链、靶向CD3的共同轻链,并进行工程化改造降低Fc区结合能力。18年12月Regeneron在ASH年会上公布了REGN1979在治疗B细胞非霍奇金淋巴瘤中取得的进展。日前公司披露了该双特异性抗体项目相关的两起死亡事件,在分析师和投资者的...
siRNA ADC 疾病领域得分 一眼洞穿机构专注的疾病领域 技术平台 公司药物应用最多的技术 靶点 公司最常开发的靶点 CD20抑制剂 在研适应症 非在研适应症 高级别B细胞淋巴瘤 最高研发阶段批准上市 首次获批国家/地区 首次获批日期2024-08-22 原研机构 Regeneron Pharmaceuticals, Inc. ...
Bispecific antibodies Follicular lymphoma (FL); Diffuse large B-cell lymphoma (DLBCL) CD20 and CD3 POZELIMAB (REGN3918) Ophthalmology, Neurology, Hematology Gene silencing, Monoclonal antibodies Myasthenia gravis, cemdisiran combination; paroxysmal nocturnal hemoglobinuria (PNH), cemdisiran combination; ...
Odronextamab (REGN1979) is a hinge-stabilized, human CD20 x CD3 IgG4-based bispecific antibody that binds CD20-expressing cells and CD3 on T cells, targeting CD20+ cells via T-cell-mediated cytotoxicity, independent of T-cell receptor-...
While Libtayo is far behind the immunotherapy leaders of Merck & Co’s Keytruda and BMS’ Opdivo, the firm is hoping to gain an edge by testing a combination of the two therapies, making it the first to investigate the combination of of a CD20xCD3 bispecific antibody with a PD-1 or PD...